Ristomycin monosulfate, ristocetin A basis (balance primarily Ristocetin B), >=90% ristocetin A basis (balance primarily Ristocetin B)

Code: r7752-250mg D2-231

Not available outside of the UK & Ireland.

Application

Ristomycin monosulfate has been used: to activate platelet and induce platelet aggregation to study the aggregation responses of platelets from buffalo, horse, pi...


read more

Your Price
£1,410.00 250MG
REQUEST

Not available outside of the UK & Ireland.

Application

Ristomycin monosulfate has been used: to activate platelet and induce platelet aggregation to study the aggregation responses of platelets from buffalo, horse, pig and sheep in in-house ristocetin cofactor von Willebrand factor (VWF:RCo) assay to measure glycoprotein Ib (GpIb) binding activity

Biochem/physiol Actions

Ristomycin possesses antibacterial activity. It may be used to diagnose von Willebrand disease and Bernard-Soulier syndrome. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb) and decreased RIPA might reduce platelet adhesion to vascular subendothelium and improve bleeding associated with uremia in patients with chronic hemodialysis.

Ristocetin activates platelets. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Together with increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb), RIPA may contribute to diminished platelet adhesion to vascular subendothelium and increased bleeding associated with uremia. Addition of ristocetin and vWf caused specific agglutination of rGPIbα-liposomes suporting the potential use of rGPIbα-liposomes to enhance platelet function in vivo and support hemostasis in thrombocytopenic individuals.

General description

Ristomycin/ristocetin is a type III glycopeptide. It is a highly glycosylated glycopeptide, previously found inAmycolatopsis lurida.

Other Notes

Glycopeptide antibiotic complex

Packaging

100, 250 mg in poly bottle

assay≥90% ristocetin A basis (balance primarily Ristocetin B)
InChI keyVUOPFFVAZTUEGW-ZNAZZOOYSA-N
InChI1S/C95H110N8O44/c1-30-47(109)18-37-20-49(30)139-50-19-35(9-16-46(50)108)59(97)84(125)102-64-68(113)33-5-11-40(12-6-33)137-52-21-38-22-53(81(52)145-95-83(76(121)72(117)56(143-95)29-134-91-78(123)73(118)67(112)32(3)136-91)147-94-82(75(120)71(116)55(27-105)142-94)146-92-77(122)69(114)48(110)28-133-92)138-41-13-7-34(8-14-41)80(144-57-25-44(96)66(111)31(2)135-57)65-89(130)101-63(90(131)132-4)43-23-39(106)24-51(140-93-79(124)74(119)70(115)54(26-104)141-93)58(43)42-17-36(10-15-45(42)107)60(85(126)103-65)98-87(128)62(38)99-86(127)61(37)100-88(64)129/h5-24,31-32,44,48,54-57,59-80,82-83,91-95,104-124H,25-29,96-97H2,1-4H3,(H,98,128)(H,99,127)(H,100,129)(H,101,130)(H,102,125)(H,103,126)/t31-,32-,44+,48+,54+,55+,56+,57-,59+,60?,61-,62+,63?,64+,65-,66-,67-,68+,69+,70+,71+,72+,73+,74-,75-,76-,77-,78+,79-,80+,82-,83+,91+,92-,93+,94+,95-/m0/s1
mode of actioncell wall synthesis | interferes
Quality Level200
SMILES stringCOC(=O)[C@@H]1NC(=O)[C@H]2NC(=O)C(NC(=O)[C@@H]3NC(=O)[C@H]4NC(=O)[C@H](NC(=O)[C@H](N)c5ccc(O)c(Oc6cc4cc(O)c6C)c5)[C@H](O)c7ccc(Oc8cc3cc(Oc9ccc(cc9)[C@H]2O[C@H]C[C@@H](N)[C@@H](O)[C@H](C)O)c8O[C@@H]O[C@H](CO[C@@H]O[C@@H](C)[C@H](O)[C@@H](O)[C@H]O)[C@@H](O)[C@H](O)[C@H]O[C@H]O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]O[C@@H]OC[C@@H](O)[C@@H](O)[C@@H]O)cc7)cccc(O)c(c)-cc(O[C@@H]O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]O)cc(O)cc1
storage temp.2-8°C
Code
Description
Unit Size
List Price
Qty
R7752-100MG
Ristomycin monosulfate, ristocetin A basis (balance primarily Ristocetin B), >=90% ristocetin A basis (balance primarily Ristocetin B)

Unit:100MG
List Price: £636.00
Source:List Price
ADD
Cas Number11140-99-1
This product has met the following criteria: